Will This Coverage Initiation Help Jazz Pharmaceuticals (JAZZ) Stock Today?

NEW YORK (TheStreet) -- JP Morgan initiated coverage on Jazz Pharmaceuticals  (JAZZ) with an "overweight" rating and a $190 price target. The firm said the company is well positioned for organic growth or the possibility of an acquisition.

The stock was up 2.28% to $155.98 in pre-market trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

JAZZ Chart JAZZ data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix